Abstract
Background: Members of the ADAM (a disintegrin and metalloprotease domain) family have emerged as critical regulators of cell-cell signaling during development and homeostasis. ADAM9 is consistently overexpressed in various human cancers, and has been shown to play an important role in tumorigenesis. However, little is known about the involvement of ADAM9 during immune-mediated processes. Results: Mining of an extensive compendium of transcriptomic datasets led to the discovery of gaps in knowledge for ADAM9 that reveal its role in immunological homeostasis and pathogenesis. The abundance of ADAM9 transcripts in the blood was increased in patients with acute infection but changed very little after in vitro exposure to a wide range of pathogen-associated molecular patterns (PAMPs). Furthermore it was found to increase significantly in subjects as a result of tissue injury or tissue remodeling, in absence of infectious processes. Conclusions: Our findings indicate that ADAM9 may constitute a valuable biomarker for the assessment of tissue damage, especially in clinical situations where other inflammatory markers are confounded by infectious processes.
Highlights
The authors give a nice review of the current literature
ADAM9 transcript was identified as a potential early stage discovery while browsing RNA-sequencing profiles of blood leukocyte populations, with the genes being ranked in alphabetical order
The abundance of ADAM9 RNA measured by RNA-seq in human blood neutrophils and monocyte samples from subjects with sepsis was found to be markedly increased as compared to uninfected controls (Figure 1; [iFigure/ GSE60424]16)
Summary
The authors give a nice review of the current literature. a link to their one study is missing. The introduction starts with the Refseq definition of ADAM9 and a thorough review of existing literature on gene function of ADAM9. It left me wondering what motivated them to ADAM9 until the first section of Results (Knowledge gap assessment). Conclusions: Our findings indicate that ADAM9 may constitute a valuable biomarker for the assessment of tissue damage, especially in clinical situations where other inflammatory markers are confounded by infectious processes
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
